/news/ - News

 >>/19770/
When you go to a supermarket and want to buy 10 bottles of whole milk for your children, you usually assume the chemicals and concentrations in these 10 bottles are the same or similar. No one would expect five of the bottles to be filled with watered-down milk while the other five were filled with yogurt.

Most store-bought foods meet our expectations because of regulations and quality control. The same criteria also exist in the pharma industry, including vaccine products.

We expect consistent physical and chemical parameters of key ingredients across different batches of drug or vaccine products. Consistency is the foundation that allows patients and consumers to have confidence in the safety and effectiveness of medications.

The CMC process—short for chemistry, manufacturing, and controls—involves defining manufacturing practices and product specifications that must be followed to ensure product safety and consistency between batches. This is a mandatory criterion for global health authorities to approve a drug or vaccine.

Controlling the quality of a traditional chemical product is relatively straightforward, but for a biological product, like an mRNA, things become more complicated.

Our DNA contains gene codes composed of nucleotides. DNA makes proteins consisting of amino acids. Between the gene code and protein, there is a bridge molecule, a “translator”—called messenger RNA (mRNA).

The full-length mRNA sequence of the Pfizer vaccine coding for the spike protein is 4,284 nucleotides in length.

It consists of a 5′ CAP structure to prime its translation into a spike protein. It works like an ignition box of a car. At the end of the translatable region, the open reading frame, there is a stop codon, which is like a car’s brakes. If a truncated mRNA does not contain a stop codon, it fails to give a “brake” signal. The protein translation process will continue endlessly.

https://www.theepochtimes.com/health/pfizer-knowingly-allowed-dangerous-components-in-its-vaccines-part-1_5060324.html

 >>/19771/
In an EMA assessment report coded EMA/CHMP/448917/2021, the EMA requested that Pfizer address the impurities of its vaccine product, which the EMA report described as “truncated and modified mRNA.”

Pfizer’s report to the EMA clearly showed that Pfizer’s vaccine contained impurities, as indicated by “Peak 1” in the graph below, based on a screenshot from page 14 of the EMA’s August 2021 report: https://www.theepochtimes.com/health/pfizer-knowingly-allowed-dangerous-components-in-its-vaccines-part-1_5060324.html

The EMA demanded that Pfizer provide monthly data on the potential of generating truncated spike proteins/peptides or other proteins/peptides causing autoimmune conditions due to molecular mimicry mechanisms. A deadline was set for July 2021, and an interim report should have been submitted by March 2021.

In an EMA assessment report on “Comirnaty, COVID-19 mRNA vaccine (nucleoside-modified),” coded as EMA/707383/2020, dated Feb. 19, 2021, on page 15 under the section “Manufacturer, process controls and characterisation,” it is stated that “During the procedure, several issues were highlighted relating to the GMP status of the manufacture of the active substance and the testing sites of the finished product for the purpose of batch release. These issues were classified as a Major Objection (MO).”

A “major objection” is a formal regulatory red flag by the EMA. If major objections remain unresolved, they preclude granting the marketing authorization.

The truncated mRNA has been discussed at length as a “Major Objection” raised by EMA in the two EMA reports we have analyzed above. Before these biological agents were deployed on the global population, EMA reviewers identified the issue of truncated mRNA and brought it up as a “major objection.”

https://www.theepochtimes.com/health/pfizer-knowingly-allowed-dangerous-components-in-its-vaccines-part-1_5060324.html

 >>/19772/
In June 2022, Trial Site News published an investigative report revealing a leaked slide presented at a meeting between Pfizer-BioNTech and the EMA. Alexandra (Sasha) Latypova, a former pharmaceutical industry executive who has worked with many companies, including Pfizer, shared the same slide in her Substack on Jan. 10, 2023.

The EMA demanded that Pfizer address these issues: “The truncated forms should be sufficiently characterized, i.e. they should be described, and it should be discussed if the fragmented species are expected to be similar between batches. In addition, the possibility of translated proteins other than the intended spike protein (S1S2), resulting from truncated and/or modified mRNA species should be addressed, and relevant protein characterization data should be provided, if available.”

Pfizer fully recognized the truncated mRNA in its vaccines. Most truncated mRNA is 1,500 to 3,500 nucleotides long with 5’ CAP,  missing the Poly(A) tail and the stop codon. They can be translated into a partial spike protein.

Unfortunately, when the mRNA goes to the end of translation, the amino acid chain does not stop prolongation, as no stop signal has been given to them. There are lots of mRNA in the cell. As there is no stop signal, in theory, another mRNA in a cell will take over and continue the unfinished job, prolonging the “spike protein.”

If the same spike mRNA takes over, prolonged spike-like proteins with multiple repeats will form. If different mRNA takes over, unknown types of proteins will be created.

A “Western blot” method is used to identify specific proteins, allowing researchers to verify the size and abundance of a protein of interest.

Because of concerns that incorrect spike protein can cause unexpected injury, the EMA required Pfizer-BioNTech to submit experimental results to demonstrate that truncated COVID-19 vaccine RNA would not produce fragment proteins.

https://www.theepochtimes.com/health/pfizer-knowingly-allowed-dangerous-components-in-its-vaccines-part-1_5060324.html